Industry Partnerships

Partnering with industrials is the way to succeed in technology development to transform an invention into a successful product for the benefit of patients and public health. The Institut Pasteur and its industrial partners are collaborating to reach this goal.

Openness to future industrial partners

Bringing an innovative solution to patient’s unmet needs is a challenge that today no single organization can achieve. Academic and industrials must now rapidly unite their expertise to provide medical, scientific and technological responses for patient’s health.
With past and current fruitful research partnerships, the Institut Pasteur is intensifying its visibility and availability to future industrial partners, from startups to large groups.

Research and Development collaborations

Industrial property - Innovation - Institut Pasteur

The Institut Pasteur's intellectual property strategy is characterized by several dominant patents.

In the early 1980s, the Institut Pasteur began to protect pioneering biotechnology inventions with patents:

  • the production of the yeast-derived hepatitis B vaccine (still marketed by GSK and Merck),
  • inventions based on the identification and molecular characterization of the HIV-1 and HIV-2 viruses,
  • various high-risk HPV strains.

These first major patents were followed by other dominant patents protecting previously unknown methods such as:

  • homologous recombination,
  • cold probes,
  • meganucleases,
  • lentiviral technology,
  • the vaccine platform based on the measles vector
 

 


What Institut Pasteur offers

By collaborating with the Institut Pasteur, industry partners can benefit from its extended diversity fields of research

Post-contract Management

Licensing Opportunities - Innovation - Institut Pasteur

In order to address the challenges of product development costs associated with the high failure rate of development collaborations, the Industrial Agreements Office builds trustworthy, long-term relationships with industrial partners in full transparency. 

 

 

Bioaster

Created in April 2012 by the Institut Pasteur and Lyonbiopole health competitiveness cluster, following the initiative of the French government, Bioaster Technology Research Institute (TRI) is working to develop a unique technological and innovative model to support the latest challenges in microbiology, in particular to:

  • Fight antimicrobial resistance

  • Improve the safety and efficacy of vaccines. Quickly diagnose infections at patient‘s bedside. Take full advantage of human and animal microbiota.

The aim of Bioaster is to boost the development of medical and nutritional solutions for human and animal health.

Bioaster has the support of high-profile academic and industrial partners. Since it was set up, it has coordinated over 53 research projects with 25 academic partners and 26 industry partners (source: Bioaster).

In between the phases of the acquisition of knowledge and providing a solution for the patient, Bioaster wants to act as a bridge between the academic and private spheres, provide a technological added value in microbiology and is an agile and collaborative organisation that reduces the risks associated with innovation.
 

See the website

Licensing Opportunities

The current available patents for licensing and tech transfer are depicted below. Please consult each of these documents of interest for more details to fetch out technologies which would meet with your needs.
 

 

R&D Collaborations

The combination of our scientific expertise and industrial awarness will enable you to find innovative solutions to meet your challenges. 

 

Other Contracts

By partnering with the Institut Pasteur, you benefit from access to science, knowledge, skills and cutting-edge infrastructures.

 

Contact us

Back to top